Related Concept Videos
Hybridoma Technology
13.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.0K
Microorganisms in Medicine and Therapeutics
1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Upstream Processing
95
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
95
Production of Pharmaceuticals
88
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
88
Recombinant DNA
92.2K
Overview
92.2K
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Thyroiditis in T cell-depleted rats: suppression of the autoallergic response by reconstitution with normal lymphoid cells.
Clinical and experimental immunology·1976
Same author
Observations on the antibody-dependent cytotoxic cell by scanning electron microscopy.
Clinical and experimental immunology·1975
Same author
Proceedings: Scanning electron microscopy of K cell activity on red cell monolayers.
British journal of cancer·1975
Same journal
Phenotypically and functionally distinct T-cell subsets in anti-tumor responses.
Immunology today·2014
Related Experiment Video
Updated: Apr 22, 2026

09:12
High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
Published on: June 10, 2025
1.4K
Summary
The job market for immunologists significantly shifted between 1980 and 1982. Academic institutions initially dominated, but industry recruitment rapidly increased, tripling overall opportunities.
Area of Science:
- Immunology
- Biomedical Research Careers
Background:
- In 1980, the landscape for postdoctoral immunology positions was primarily academic.
- Industry offered a smaller but present segment of opportunities.
Purpose of the Study:
- To analyze the changes in the job market for postdoctoral scientists in immunology.
- To compare recruitment trends between academic institutions and industry.
Main Methods:
- Analysis of job advertisements in the journal "Science" from 1980 and 1982.
- Categorization of positions by sector: academic vs. industry.
Main Results:
- In 1980, approximately 80 immunology jobs were advertised, with 80% in academia and 20% in industry.
- By 1982, advertised positions increased to around 120, with industry accounting for 50% of the offers.
- This indicates a substantial three-fold increase in total recruitment.
Conclusions:
- The period saw a dramatic expansion in the immunology job market.
- Industry emerged as a major recruiter, significantly altering the career landscape for immunologists.

